Equine osteoarthritis: intra-articular triamcinolone vs hyaluronic acid — MAYBE (weak evidence)

In horses with OA, does intra-articular triamcinolone improve lameness and synovial measures more than hyaluronic acid, and at what cartilage cost?

Shelf #198 · gate-verified and approved by the developer

MAYBE (weak evidence): EXPERIMENTAL-MODEL LIMIT, on the face of this pack: every carded study used a surgically induced osteochondral-fragment / experimentally induced osteoarthritis model in research horses (Colorado State programme and successors), not client-owned horses with naturally occurring OA — and no carded study compares triamcinolone against hyaluronic acid head-to-head, so the comparison is indirect, across separate placebo/saline-controlled experiments. In the Frisbie 1997 randomised model study, intra-articular triamcinolone acetonide 12 mg (days 13 and 27) made fragment-bearing horses significantly less lame than placebo controls, with lower synovial total protein, higher hyaluronan and glycosaminoglycan concentrations, less synovial inflammation/fibrosis, and — against the usual cartilage-cost worry — significantly better articular cartilage histomorphological parameters than placebo. In the comparable induced-OA model, intra-articular sodium hyaluronan produced no changes in clinical signs versus saline controls, though fibrillation was histologically less (Frisbie 2009); intravenous hyaluronate in the fragment model did lower lameness scores versus placebo (Kawcak 1997). Read together, triamcinolone has the stronger lameness signal and no cartilage cost was detected in-model at the dose and schedule carded — but indirect, small, experimental evidence cannot carry more than MAYBE (weak evidence) for the head-to-head question. Drafted Nov 10, 2026 (VetMed build, topic #198); all figures from abstracts fetched and verified at drafting.

Frisbie 1997: intra-articular triamcinolone 12 mg made fragment-model horses significantly less lame than placebo, with better synovial and cartilage histology

Randomized controlled trial (record's publication types: Clinical Trial, Randomized Controlled Trial; abstract states horses randomly assigned)

Who: Horses: 18 research horses in an experimental setting (Colorado State osteochondral-fragment exercise model), randomly assigned to 3 groups; an osteochondral chip fragment was created in one randomly chosen intercarpal joint of each horse, all horses were treated intra-articularly on days 13 and 27 after surgery and exercised on a high-speed treadmill for 6 weeks from day 14 — placebo controls received polyionic fluid in both joints, the triamcinolone (TA) control group received 12 mg TA in the non-fragment joint, and the TA treated group received 12 mg TA in the fragment-bearing joint (opposite joint polyionic fluid in both TA groups).

Result: Horses in the TA treated group were significantly less lame than horses in the placebo control and TA control groups. Horses in either TA group had lower total protein, and higher hyaluronan and glycosaminoglycan concentrations in synovial fluid, than placebo controls. Synovial membrane from TA-group horses had significantly less inflammatory cell infiltration, subintimal hyperplasia and subintimal fibrosis than controls. Articular cartilage histomorphological parameters were significantly better in the TA groups than in the placebo group. The authors concluded that the results support favourable effects of TA on lameness and on synovial fluid, synovial membrane and cartilage morphological parameters compared with placebo.

Watch out: Experimental induced-fragment model in 18 research horses — not naturally occurring OA in client-owned horses. The record does not state that lameness assessors or histologists were blinded, and blinding is not claimed here. 'Cartilage cost' is answered only for this dose (12 mg), schedule (two injections) and model duration; repeated or higher-dose use in clinical joints is outside this record. There is no hyaluronic acid arm — the TA-versus-HA comparison on this shelf is indirect.

Frisbie DD, Kawcak CE, Trotter GW, Powers BE, Walton RM, McIlwraith CW. Effects of triamcinolone acetonide on an in vivo equine osteochondral fragment exercise model. Equine veterinary journal. 1997;29(5):349-59. PMID: 9306060. Registry ID: none in the record. MeSH: Animals · Anti-Inflammatory Agents/administration & dosage,pharmacology · Cartilage Diseases/drug therapy,etiology,veterinary · Cartilage, Articular/chemistry,drug effects,injuries · Glycosaminoglycans/analysis,metabolism · Horse Diseases/drug therapy,etiology,metabolism · Horses/injuries,metabolism,physiology · Hyaluronic Acid/analysis,metabolism · Hyperplasia/drug therapy,etiology,veterinary · Injections, Intra-Articular/methods,veterinary · Physical Conditioning, Animal/adverse effects,physiology · Synovial Fluid/chemistry,drug effects,metabolism · Synovial Membrane/chemistry,drug effects,metabolism · Triamcinolone Acetonide/administration & dosage,pharmacology

Frisbie 2009: intra-articular hyaluronan changed no clinical signs vs saline in induced OA, though cartilage fibrillation was histologically less

Randomized controlled trial (record's publication types: Comparative Study, Randomized Controlled Trial)

Who: Horses: 24 research horses in an experimental setting with osteoarthritis induced arthroscopically in one middle carpal joint of every horse; 8 horses received intra-articular hyaluronan 20 mg plus amikacin 125 mg on study days 14, 21 and 28, 8 received intra-articular polysulfated glycosaminoglycan 250 mg plus amikacin, and 8 control horses received intra-articular saline 2 mL plus amikacin on the same days; clinical, radiographic, synovial fluid, gross, histologic, histochemical and biochemical findings were evaluated. No adverse treatment-related events were detected.

Result: Induced osteoarthritis caused substantial changes in lameness, response to flexion, joint effusion and radiographic findings. No changes in clinical signs were seen with polysulfated glycosaminoglycan or hyaluronan, compared with control horses (synovial fluid effusion was reduced with polysulfated glycosaminoglycan only). Histologically, significantly less fibrillation was seen with hyaluronan treatment compared with controls, and synovial membrane vascularity and subintimal fibrosis were significantly reduced with polysulfated glycosaminoglycan. The authors concluded that both agents had beneficial disease-modifying effects.

Watch out: The hyaluronan lameness/clinical-signs result was null against saline in this model — the positive hyaluronan finding is a histological one (less fibrillation). All horses also received intra-articular amikacin. Experimental induced OA in 24 research horses, 8 per arm; the record does not state assessor blinding in the abstract and none is claimed. No triamcinolone arm — see the synthesis for the indirect nature of the comparison.

Frisbie DD, Kawcak CE, McIlwraith CW, Werpy NM. Evaluation of polysulfated glycosaminoglycan or sodium hyaluronan administered intra-articularly for treatment of horses with experimentally induced osteoarthritis. American journal of veterinary research. 2009;70(2):203-9. PMID: 19231952. Registry ID: none in the record. MeSH: Amikacin · Analysis of Variance · Animals · Arthrography/veterinary · Glycosaminoglycans/administration & dosage,therapeutic use · Horse Diseases/diagnostic imaging,drug therapy · Horses · Hyaluronic Acid/administration & dosage,therapeutic use · Injections, Intra-Articular · Osteoarthritis/diagnostic imaging,drug therapy,veterinary · Synovial Fluid/chemistry

Kawcak 1997: intravenous hyaluronate lowered lameness scores and synovial total protein and prostaglandin E2 vs placebo in the fragment model — with no cartilage glycosaminoglycan effect

Randomized controlled trial (record's publication types: Clinical Trial, Randomized Controlled Trial)

Who: Horses: 12 clinically normal research horses, 2 to 7 years of age, in an experimental setting; an osteochondral fragment was created at the distal aspect of the radiocarpal bone of one randomly chosen middle carpal joint, and horses were treated with hyaluronate 40 mg or saline placebo intravenously once a week for 3 consecutive weeks (days 13, 20 and 27 after surgery), with treadmill exercise 5 days per week from day 15 to day 72, synovial fluid sampling from both middle carpal joints on days 0, 13, 20, 27, 34 and 72, and synovial membrane and cartilage histology at euthanasia on day 72.

Result: Horses treated with intravenous hyaluronate had lower lameness scores (were less lame) and significantly better synovial membrane histologic scores, and significantly lower concentrations of total protein and prostaglandin E2 in synovial fluid 72 days after surgery, compared with placebo-treated horses. Intravenous hyaluronate had no significant effects on glycosaminoglycan content, synthetic rate or morphologic scoring in articular cartilage, or on other synovial fluid measurements. The authors concluded that intravenous hyaluronate appears to alleviate lameness by interacting with synoviocytes and decreasing inflammatory mediator production and release.

Watch out: This hyaluronate was given INTRAVENOUSLY, not intra-articularly — it is carded because it is the hyaluronan record in the same Colorado State fragment model as the triamcinolone study, and the route difference must not be blurred: the intra-articular hyaluronan record is Frisbie 2009 above, whose clinical-signs result was null. Twelve research horses, experimental model; assessor blinding is not stated in the record and is not claimed.

Kawcak CE, Frisbie DD, Trotter GW, McIlwraith CW, Gillette SM, Powers BE, Walton RM. Effects of intravenous administration of sodium hyaluronate on carpal joints in exercising horses after arthroscopic surgery and osteochondral fragmentation. American journal of veterinary research. 1997;58(10):1132-40. PMID: 9328667. Registry ID: none in the record. MeSH: Animals · Arthroscopy/methods,veterinary · Carpus, Animal/drug effects,injuries,pathology · Cartilage, Articular/chemistry,metabolism,pathology · Dinoprostone/analysis,metabolism · Fractures, Bone/metabolism,pathology,veterinary · Glycosaminoglycans/analysis,metabolism · Horse Diseases/metabolism,pathology,physiopathology · Horses · Hyaluronic Acid/administration & dosage,pharmacology · Incidence · Injections, Intravenous/methods,veterinary · Lameness, Animal/epidemiology,etiology,pathology · Physical Conditioning, Animal/physiology · Synovial Fluid/chemistry · Synovial Membrane/drug effects,metabolism,pathology · Time Factors

Synthesis: no head-to-head trial exists — triamcinolone carries the stronger in-model lameness signal and no detected cartilage cost; intra-articular hyaluronan's in-model benefit was histological only

Synthesis

Who: Synthesis of the cards above: Frisbie 1997 (18 research horses, osteochondral-fragment exercise model, intra-articular triamcinolone vs placebo), Frisbie 2009 (24 research horses, arthroscopically induced OA, intra-articular hyaluronan vs saline) and Kawcak 1997 (12 research horses, same fragment model, intravenous hyaluronate vs placebo) — all experimental models, none in naturally occurring clinical OA.

Result: Indirectly compared through their separate placebo/saline controls: (1) lameness — triamcinolone intra-articularly significantly reduced lameness; intra-articular hyaluronan changed no clinical signs; intravenous hyaluronate reduced lameness scores. (2) Synovial measures — triamcinolone lowered total protein and raised hyaluronan/glycosaminoglycan concentrations; intravenous hyaluronate lowered total protein and prostaglandin E2. (3) Cartilage — triamcinolone groups had significantly better cartilage histomorphology than placebo (no cartilage cost detected in-model), while hyaluronan showed less fibrillation (intra-articular) or no cartilage effect (intravenous). The pattern favours triamcinolone for lameness in these models, but different studies, routes, doses and endpoints make this a hypothesis-grade comparison: MAYBE (weak evidence).

Watch out: EXPERIMENTAL-MODEL LIMIT: surgically induced fragments/OA in young research horses under treadmill exercise do not reproduce years of naturally occurring OA in client-owned horses, and none of the carded records establishes assessor blinding. In-vitro cartilage-explant corticosteroid studies exist in this literature but are not carded: VetMed does not accept in-vitro work yet, and they cannot carry a clinical claim.

Synthesis of Frisbie DD et al. PMID: 9306060; Frisbie DD et al. PMID: 19231952; Kawcak CE et al. PMID: 9328667. Registry IDs as on the individual cards.

Back to the library index · VetMed home

VetMed is an educational resource, not veterinary advice.